Comparative Pharmacology
Head-to-head clinical analysis: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE versus DIUCARDIN.
Head-to-head clinical analysis: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE versus DIUCARDIN.
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE vs DIUCARDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and further lowering blood pressure.
Thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
1 tablet (candesartan cilexetil 16 mg/hydrochlorothiazide 12.5 mg) orally once daily. Maximum dose: 1 tablet (32 mg/25 mg) once daily.
Hydrochlorothiazide 25-50 mg orally once daily, titrated based on response. Maximum dose 100 mg/day.
None Documented
None Documented
Candesartan: Terminal t1/2 ~9 hours (linear); clinically, once-daily dosing provides 24-hour antihypertensive effect. Hydrochlorothiazide: Terminal t1/2 ~6-15 hours (averaging 10 hours), prolonged in renal impairment.
Terminal elimination half-life is approximately 18-24 hours in normal renal function. This prolongs significantly in renal impairment, requiring dose adjustment.
Candesartan: ~33% renal, ~67% biliary/fecal as unchanged drug and inactive metabolites. Hydrochlorothiazide: ≥95% renal as unchanged drug.
Primarily renal excretion: approximately 60-70% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal elimination accounts for about 20-30%, with some enterohepatic circulation.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic